• Sana Biotechnology entered a stock purchase agreement to sell 7,507,507 shares to Mayo Clinic at USD 3.33 per share for about USD 25 million in gross proceeds.
• Mayo Clinic can elect to buy another 7,507,507 shares at the same price by Aug. 31, 2026 for an additional USD 25 million.
• Closing for the initial sale is expected around April 15, 2026.
• Proceeds are earmarked for development of programs tied to a separate collaboration, including SC451.
• Sana said cash of USD 138.4 million at Dec. 31, 2025, combined with about USD 24.9 million in expected net proceeds from the initial sale, should fund operations into 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-152868), on April 13, 2026, and is solely responsible for the information contained therein.